Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer

(2015) Sandrina Lambrechts et al.   BMC Pharmacology & Toxicology

Biomarkers for Systemic Therapy in Ovarian Cancer

(2014) Zsofia Penzvalto et al.   CURRENT CANCER DRUG TARGETS

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic markers for prediction of treatment outcomes in ovarian cancer

(2014) E Caiola et al.   PHARMACOGENOMICS JOURNAL

Prognostic biomarkers in endometrial and ovarian carcinoma

(2014) Xavier Matias-Guiu et al.   VIRCHOWS ARCHIV

Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study

(2013) William P. Tew et al.   CANCER

Improvement of a Predictive Model of Castration-Resistant Prostate Cancer: Functional Genetic Variants in TGFβ1 Signaling Pathway Modulation

(2013) Ana L. Teixeira et al.   PLoS One

Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients

(2013) Ana L. Teixeira et al.   TUMOR BIOLOGY

Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs

(2012) J. J.G. Marin et al.   CURRENT CANCER DRUG TARGETS

Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy

(2012) Ignacio Romero et al.   ENDOCRINOLOGY

Cancer Pharmacogenomics

(2011) S W Paugh et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer

(2011) Troels K. Bergmann et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: A systematic review

(2011) Ivan Diaz-Padilla et al.   GYNECOLOGIC ONCOLOGY

Part 3: Pharmacogenetic Variability in Phase II Anticancer Drug Metabolism

(2011) M. J. Deenen et al.   ONCOLOGIST

Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins

(2011) Andrey Khrunin et al.   PHARMACOGENOMICS

Current drugs still have potential in advanced ovarian cancer

(2010) Thomas Hogberg   Nature Reviews Clinical Oncology

Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk

(2009) Nada Božina et al.   Arhiv za Higijenu Rada i Toksikologiju-Archives of Industrial Hygiene and Toxicology

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Novel strategies for reversing platinum resistance

(2009) Mian M.K. Shahzad et al.   DRUG RESISTANCE UPDATES

Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study

(2009) Hee Seung Kim et al.   GYNECOLOGIC ONCOLOGY

Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients

(2009) A V Khrunin et al.   PHARMACOGENOMICS JOURNAL

Ovarian Cancer

(2008) Kathleen R. Cho et al.   Annual Review of Pathology-Mechanisms of Disease

Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer

(2008) Franco Muggia   GYNECOLOGIC ONCOLOGY

Pharmaco(epi)genomics in ovarian cancer

(2008) Adam JW Paige et al.   PHARMACOGENOMICS